Clinical manifestations and immune markers of non-HIV-related CMV retinitis.
CD4 + lymphocytes
CMV retinitis
Cytomegalovirus
Immunoglobulins
Immunosuppression
Infectious uveitis
Lymphocyte count
Recurrence
Solid organ transplant
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
07
11
2023
accepted:
23
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
Since the HIV epidemic in the 1980s, CMV retinitis has been mainly reported in this context. CMV retinitis in persons living with HIV is usually observed when CD4 + cells are below 50 cells/mm3. This study aims to describe the immune markers of non-HIV-related CMV retinitis as well as to describe its clinical manifestations and outcomes. Retrospective chart review of consecutive patients with CMV retinitis not related to HIV seen at the uveitis clinic of Jules Gonin Eye Hospital between 2000 and 2023. We reported the clinical manifestations and outcomes of the patients. We additionally assessed immune markers during CMV retinitis (leukocyte, lymphocyte, CD4 + cell and CD8 + cell counts as well as immunoglobulin levels). Fifteen patients (22 eyes) were included. Underlying disease was hematologic malignancy in 9 patients, solid organ transplant in 3 patients, rheumatic disease in 2 patients and thymoma in one patient. The median time between the onset of underlying disease and the diagnosis of retinitis was 4.8 years. Lymphopenia was observed in 8/15 patients (mild = 3, moderate = 4, severe = 1), and low CD4 counts were observed in 9/12 patients, with less than 100 cells/mm3 in 4 patients. Hypogammaglobulinemia was detected in 7/11 patients. Retinitis was bilateral in 7/15 patients, and severe visual loss was frequent (5/19 eyes). Disease recurrence was seen in 7/13 patients at a median time of 6 months after initial diagnosis. No differences in immune markers were observed in patients with vs. without recurrence. CMV retinitis is a rare disorder that can affect patients suffering any kind of immunodeficiency. It is associated with a high visual morbidity despite adequate treatment. CD4 + cell counts are usually higher than those in HIV patients, but B-cell dysfunction is common.
Sections du résumé
BACKGROUND
BACKGROUND
Since the HIV epidemic in the 1980s, CMV retinitis has been mainly reported in this context. CMV retinitis in persons living with HIV is usually observed when CD4 + cells are below 50 cells/mm3. This study aims to describe the immune markers of non-HIV-related CMV retinitis as well as to describe its clinical manifestations and outcomes.
METHODS
METHODS
Retrospective chart review of consecutive patients with CMV retinitis not related to HIV seen at the uveitis clinic of Jules Gonin Eye Hospital between 2000 and 2023. We reported the clinical manifestations and outcomes of the patients. We additionally assessed immune markers during CMV retinitis (leukocyte, lymphocyte, CD4 + cell and CD8 + cell counts as well as immunoglobulin levels).
RESULTS
RESULTS
Fifteen patients (22 eyes) were included. Underlying disease was hematologic malignancy in 9 patients, solid organ transplant in 3 patients, rheumatic disease in 2 patients and thymoma in one patient. The median time between the onset of underlying disease and the diagnosis of retinitis was 4.8 years. Lymphopenia was observed in 8/15 patients (mild = 3, moderate = 4, severe = 1), and low CD4 counts were observed in 9/12 patients, with less than 100 cells/mm3 in 4 patients. Hypogammaglobulinemia was detected in 7/11 patients. Retinitis was bilateral in 7/15 patients, and severe visual loss was frequent (5/19 eyes). Disease recurrence was seen in 7/13 patients at a median time of 6 months after initial diagnosis. No differences in immune markers were observed in patients with vs. without recurrence.
CONCLUSION
CONCLUSIONS
CMV retinitis is a rare disorder that can affect patients suffering any kind of immunodeficiency. It is associated with a high visual morbidity despite adequate treatment. CD4 + cell counts are usually higher than those in HIV patients, but B-cell dysfunction is common.
Identifiants
pubmed: 39107686
doi: 10.1186/s12879-024-09653-x
pii: 10.1186/s12879-024-09653-x
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787Informations de copyright
© 2024. The Author(s).
Références
Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–13.
doi: 10.1002/rmv.655
pubmed: 20564615
Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, Rickman LS, et al. Correlation between CD4 + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575–82.
doi: 10.1016/S0002-9394(14)71453-9
pubmed: 8098183
Bhat P, Jackson AT, Foster CS. Infectious uveitis. In: Ocular Disease [Internet]. Elsevier; 2010 [cited 2022 Apr 29]. pp. 654–65. https://linkinghub.elsevier.com/retrieve/pii/B9780702029837000838 .
Manuel O, Avery RK. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity. Curr Opin Infect Dis. 2021;34(4):307–13.
doi: 10.1097/QCO.0000000000000746
pubmed: 34074879
Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Cytomegalovirus Retinitis. Am J Ophthalmol. 2021;228:245–54.
doi: 10.1016/j.ajo.2021.03.051
Holland GN, Buhles WC, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV retinopathy. Study Group. Arch Ophthalmol Chic Ill 1960. 1989;107(12):1759–66.
Cancer Therapy Evaluation Program, Co. Common Terminology Criteria for Adverse Events [Internet]. 2006 [cited 2022 Apr 29]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf .
Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transpl. 2008;13(6):581–5.
doi: 10.1097/MOT.0b013e3283186bbc
Iu LP, Fan MC, Lau JK, Chan TS, Kwong YL, Wong IY. Long-term follow-up of Cytomegalovirus Retinitis in Non-HIV Immunocompromised patients: clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53.
doi: 10.1016/j.ajo.2016.03.015
pubmed: 27005706
Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol. 2004;138(3):338–46.
doi: 10.1016/j.ajo.2004.04.015
pubmed: 15364214
Jeon S, Lee WK. Cytomegalovirus retinitis in a human immunodeficiency virus-negative cohort: long-term management and complications. Ocul Immunol Inflamm. 2015;23(5):392–9.
doi: 10.3109/09273948.2014.985385
pubmed: 25760914
Sadik MT, Aksu Ceylan N, Cebeci Z, Kir N, Oray M, Tugal-Tutkun I. Patterns of cytomegalovirus retinitis at a tertiary referral center in Turkey. Int Ophthalmol. 2021;41(9):2981–92.
doi: 10.1007/s10792-021-01857-3
pubmed: 33885967
Son G, Lee JY, Kim JG, Kim YJ. Clinical features of cytomegalovirus retinitis after solid organ transplantation versus hematopoietic stem cell transplantation. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2021;259(3):585–91.
doi: 10.1007/s00417-020-04871-w
Yoon M, Oh J, Chun KH, Lee CJ, Kang SM. Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation. Sci Rep. 2021;11(1):1426.
doi: 10.1038/s41598-020-80790-4
pubmed: 33446808
pmcid: 7809401
Corona-Nakamura AL, Monteón-Ramos FJ, Troyo-Sanromán R, Arias-Merino MJ, Anaya-Prado R. Incidence and Predictive Factors for Cytomegalovirus Infection in Renal Transplant Recipients. Transplant Proc. 2009;41(6):2412–5.
Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A Meta-analysis: risk of infections in severe hypogammaglobulinemia. Am J Transpl. 2013;13(10):2601–10.
doi: 10.1111/ajt.12401
Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J, Drozd-Sokołowska J, Kmin E, Chlebus M, Szczypińska K, et al. Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation—a single-center analysis. Ann Hematol. 2021;100(12):3007–16.
doi: 10.1007/s00277-021-04649-y
pubmed: 34477951
pmcid: 8593025
Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, et al. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. BMC Infect Dis. 2018;18(1):179.
doi: 10.1186/s12879-018-3075-z
pubmed: 29661141
pmcid: 5902940
Carbone J, Rodriguez-Ferrero ML, Lopez-Hoyos M, Karanovic B, Arias M, Rodrigo E et al. IgG Hypogammaglobulinemia is a Risk Factor of Cytomegalovirus Infection in a Multicenter Study in Kidney Transplantation. Transplantation [Internet]. 2018;102. https://journals.lww.com/transplantjournal/Fulltext/2018/07001/IgG_Hypogammaglobulinemia_is_a_Risk_Factor_of.573.aspx .
Chess Q, Daniels J, North E, Macris NT. Serum immunoglobulin elevations in the acquired immunodeficiency syndrome (AIDS): IgG, IgA, IgM, and IgD. Diagn Immunol. 1984;2(3):148–53.
pubmed: 6499376
Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and Immunoglobulin Analysis in HIV-Infected patients. Am J Clin Pathol. 2007;128(4):596–603.
doi: 10.1309/QWTQFGA9FXN02YME
pubmed: 17875511
Nozarian Z, Mehrtash V, Abdollahi A, Aeinehsazi S, Khorsand A, Eftekhar-Javadi A, et al. Serum protein electrophoresis pattern in patients living with HIV: frequency of possible abnormalities in Iranian patients. Iran J Microbiol. 2019;11(5):440–7.
pubmed: 32148675
pmcid: 7049319
Zemlin AE, Ipp H, Maleka S, Erasmus RT. Serum protein electrophoresis patterns in human immunodeficiency virus-infected individuals not on antiretroviral treatment. Ann Clin Biochem. 2015;52(Pt 3):346–51.
doi: 10.1177/0004563214565824
pubmed: 25487599
Ohmoto A, Fuji S, Shultes KC, Savani BN, Einsele H. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transpl. 2022;57(6):874–80.
doi: 10.1038/s41409-022-01680-z
Florescu DF, Kalil AC, Qiu F, Grant W, Morris MC, Schmidt CM, et al. Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia? Clin Transpl. 2014;28(11):1249–55.
doi: 10.1111/ctr.12458
Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2004;33(4):431–4.
doi: 10.1038/sj.bmt.1704369
Kim JY, Hong SY, Park WK, Kim RY, Kim M, Park YG, et al. Prognostic factors of cytomegalovirus retinitis after hematopoietic stem cell transplantation. PLoS ONE. 2020;15(9):e0238257.
doi: 10.1371/journal.pone.0238257
pubmed: 32877457
pmcid: 7467317
Prakash K, Chandorkar A, Saharia KK. Utility of CMV-Specific Immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update. Diagnostics. 2021;11(5):875.
doi: 10.3390/diagnostics11050875
pubmed: 34068377
pmcid: 8153332
Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 2018;20(4):4.
doi: 10.1007/s11908-018-0610-4
pubmed: 29542023
Mavropoulou E, Ternes K, Mechie NC, Bremer SCB, Kunsch S, Ellenrieder V, et al. Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome. BMJ Open Gastroenterol. 2019;6(1):e000258.
doi: 10.1136/bmjgast-2018-000258
pubmed: 30899538
pmcid: 6398871
Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Kidney and Transplant Group, editor. Cochrane Database Syst Rev [Internet]. 2015 Dec 3 [cited 2022 Sep 2]; https://doi.org/10.1002/14651858.CD007746.pub2 .